Heart failure & cardiomyopathies
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy
Authors' conclusion
In a contemporary cohort of tafamidis-treated patients with ATTR-CM, 39% of patients died over a median of 43 months.
Study context
- Population
- Patients with ATTR-CM treated with tafamidis at 5 US amyloidosis centres, 2018–2021
- Participants
- 624 patients
- Outcome
- All-cause mortality
Methodological detailsmulticentre, 5 US amyloidosis centres
- Multicentre
- 5 US amyloidosis centres
Main finding
As reported in the abstract
Died over median follow-up 43.2 months (Q1-Q3: 25.2-52.8 months)
241 patients
38.6%
Probability of freedom from death at 65 months
54.1%
95% CI 47.4%–60.4%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Survival, tafamidis started within 6 months of ATTR-CM diagnosis (subgroup) · 65 months | Tafamidis within 6 months 49.6% (95% CI 37.6%–60.5%) |
- Survival, tafamidis started within 6 months of ATTR-CM diagnosis (subgroup): n = 397, 63.6%
Original publication
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC CardioOncol. Published 11 February 2025. doi:10.
Summarised from the published abstract; every number is checked against it